Biologics Contract Development Market Growth & Trends
The global biologics contract development market size is expected to reach USD 13.3 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 10.5% from 2022 to 2030. The market comprises organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications, including drug screening, gene functional studies, and biologic production.
The market is segmented on the basis of biological source, product service (upstream and downstream), and indication. Factors such as the increasing adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries; and an increase in outsourcing of R&D activities are paving the way for the growth of the market. During the COVID-19 pandemic, a significant number of CROs partnered with biotechnology companies for R&D in COVID-19 vaccines. In 2022, there will be a significant number of companies undergoing research for a potential COVID-19 vaccine owing to the rising cases. This is expected to have a positive impact on the market.
Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and the amalgamation of advanced and specialized technologies. For instance, In September 2021, Curia Global, Inc., formerly AMRI, leading contract research, development, and manufacturing firm, acquired LakePharma Inc., a California-based biologics drug discovery, development, and manufacturing company. Many biopharma and pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development organization market growth in the coming years.
During the COVID-19 pandemic, the majority of clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to its rising incidence. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. According to the IQVIA report Oncology Trends 2022, the number of cancer clinical trials increased significantly in 2021. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.
Request a free sample copy or view report summary: Biologics Contract Development Market Report
Biologics Contract Development Market Report Highlights
Mammalian source emerged as the largest product segment in 2021, as the majority of research activities are being carried out using mammalian cell lines
The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs)
North America dominated the market in 2021. An increase in strategic acquisitions and partnerships and a rise in demand for specialized testing services are likely to have a positive impact on the market
In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period
Comments